Neonatal leukemia harboring KAT6A::EP300 fusion: To treat or not to treat?

IF 2.4 3区医学 Q2 HEMATOLOGY Pediatric Blood & Cancer Pub Date : 2024-09-22 DOI:10.1002/pbc.31346

Flavia Gava, Paulo Vidal Campregher, Victoria Tomaz, Marina Ferreira Candido, Roberta Petroni, Fernando Chahud, Carlos Alberto Scrideli, Elvis Terci Valera

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

携带 KAT6A::EP300 融合基因的新生儿白血病：治疗还是不治疗？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pediatric Blood & Cancer 医学-小儿科

CiteScore

4.90

自引率

9.40%

发文量

546

审稿时长

1.5 months

期刊介绍： Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.

期刊最新文献

Burden of SARS-CoV-2 infection prior to vaccine eligibility among immunocompromised children aged 1-11 years at a pediatric tertiary referral hospital in Toronto, Canada. CHIEF: A retrospective self-control study of children with severe hemophilia A without inhibitors comparing emicizumab to FVIII prophylaxis. Extreme thrombocytosis negative for GATA1 mutation in an infant with trisomy 21. Immune or inherited thrombocytopenia? A population-based cohort study on children and adolescents presenting with a low platelet count. Roles of pediatric surgeons in palliative pediatric oncology.